Results of an unannounced proficiency test for the quantification of hepatitis C virus (HCV) RNA in Shanghai, China
- 55 Downloads
Sensitive and accurate hepatitis C virus (HCV) RNA quantification is essential for the management of chronic hepatitis C therapy. Currently, in Shanghai, China, many laboratories offer to quantify the HCV RNA level using various reverse transcription-polymerase chain reaction (rRT-PCR) assays, but the degree of proficiency may vary between them. The objective of this study was to realistically evaluate the performance of clinical laboratories for HCV RNA quantification by a new way of proficiency test program (unannounced inspection). Inactivated chimeric influenza viral particles (CIVP) encapsulating specific RNA sequences of HCV were prepared as positive samples. The sample panel, which consisted of two negative and eight positive samples with different concentrations of CIVP (25 IU/ml to 2.5×106 IU/ml), was distributed to 40 clinical laboratories for HCV RNA quantification. The results reported by the participating laboratories were compared and scored. It was found that 75 % (30/40) of the laboratories obtained an acceptable or better performance score, while the other 10 laboratories had room for improvement. Reported results for individual samples ranged from 125 IU/ml (minimum) to 6.0×104 IU/ml (maximum). The greatest variation was observed for samples with a relatively low concentration. Interlaboratory variability among replicate samples was significantly greater than intralaboratory variability (p < 0.05). Our results demonstrate that there is room for some laboratories to improve their performance in the quantification of HCV RNA in Shanghai. Additionally, this study underlines the importance of unannounced inspection for realistically monitoring the quality of diagnostic laboratories.
KeywordsProficiency test Unannounced inspection HCV RNA rRT-PCR Quality assessment
We appreciate those laboratories and institutions that participated in the PT schemes for this survey on HCV RNA quantification. This work was supported by the Natural Science Foundation of Shanghai (No. 15ZR1436200).
Compliance with ethical standards
Conflict of interest
The authors state that there are no conflicts of interest with regard to publication of this article.
- 6.Gentili G, Pisani G, Saldanha J, Cristiano K, Wirz M, Bisso GM, Mele C, Participants EQA (2003) High proficiency in detecting the six major hepatitis C virus genotypes of laboratories involved in testing plasma by nucleic acid amplification technology. Vox Sang 85(2):114–116CrossRefPubMedGoogle Scholar
- 7.Mancini C, Pisani G, Azzi A, Luisa Zerbini M, Gentili G, Mario Bisso G, Participants MS (2004) Inter-laboratory comparison of qualitative and quantitative detection of hepatitis C (HCV) virus RNA in diagnostic virology: a multicentre study (MS) in Italy. J Clin Virol 30(4):313–319CrossRefPubMedGoogle Scholar
- 9.Shiffman ML, Ferreira-Gonzalez A, Reddy KR, Sterling RK, Luketic VA, Stravitz RT, Sanyal AJ, Garrett CT, De Medina M, Schiff ER (2003) Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practice. Am J Gastroenterol 98(5):1159–1166CrossRefPubMedGoogle Scholar
- 10.Pisani G, Cristiano K, Marino F, Luciani F, Bisso GM, Mele C, Adriani D, Gentili G, Wirz M (2009) Quantification of hepatitis C virus (HCV) RNA in a multicenter study: implications for management of HCV genotype 1-infected patients. J Clin Microbiol 47(9):2931–2936CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Wang LN, Zhang R, Shen ZY, Chen WX, Li JM (2008) External quality assessment on detection of hepatitis C virus RNA in clinical laboratories of China. Chin Med J (Engl) 121(11):1032–1036Google Scholar
- 16.Wang X, Zhang W, Liu F, Zheng M, Zheng D, Zhang T, Yi Y, Ding Y, Luo J, Dai C, Wang H, Sun B, Chen Z (2012) Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge. Arch Virol 157(8):1451–1461CrossRefPubMedGoogle Scholar
- 20.Vermehren J, Maasoumy B, Maan R, Cloherty G, Berkowski C, Feld JJ, Cornberg M, Pawlotsky JM, Zeuzem S, Manns MP, Sarrazin C, Wedemeyer H (2016) Applicability of hepatitis C virus RNA viral load thresholds for 8-week treatments in patients with chronic hepatitis C virus genotype 1 infection. Clin Infect Dis 62(10):1228–1234CrossRefPubMedGoogle Scholar